Shanghai, China-Recently, the second-generation balloon catheter-Alwide Plus Balloon Catheter (hereinafter referred to as "Alwide Plus") self-developed by MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) was approved for marketing by Saudi Food & Drug Authority.

London, UK - November 19th - November 21st, 2023, evidence-based data from the VitaFlow^® Transcatheter Aortic Valve (VitaFlow^®), developed by MicroPort^® CardioFlow (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK), were revealed on PCR London Valves, a leading global event on structural heart diseases. The data showed that the long-term and excellent clinical outcomes of VitaFlow^® have reached the international mainstream level, and this is also the first time for the domestically-developed transcatheter aortic valve system to publish 7-year long-term follow-up data in the international authoritative academic arena in the field of interventional treatment of heart valve disease.

Shanghai, China, MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) has recently received marketing approval for its VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (hereinafter referred to as "VitaFlow Liberty^®" ) and Alwide^® Plus balloon catheter (hereinafter referred to as "Alwide^® Plus") from the Indonesian Ministry of Health (MOH).